Skip to content Skip to footer
Subscribe Now
NEWS

SystImmune and BMS’ Izalontamab Brengitecan Secures the US FDA’s Breakthrough Therapy Designation to Treat EGFRm NSCLC

Shots: The US FDA has granted BTD to izalontamab brengitecan (iza-bren) for LA/M NSCLC with EGFR exon 19 deletions or exon 21 L858R mutations progressing on or after EGFR TKI & Pt-based CT Designation was backed by data from 3 ongoing trials: BL-B01D1-101 & BL-B01D1-203 in China led by Sichuan Biokin, & the global BL-B01D1-LUNG-101…
August 18, 2025

Read more

Exclusive_Noelle Bush_2024
EXCLUSIVE

Noelle Bush in an Enlightening Interview with PharmaShots Shares Insights from the It Takes 2 Awareness Program

Shots:  Exemplifying awareness campaign at its best with a hint of contemporary music, “It takes 2” by Boehringer Ingelheim and Eli Lilly is a noble initiative aimed at integrating UACR testing with eGFR for better screening of CKD  Noelle Bush, in an engaging conversation with PharmaShots, cites the growing incidences of CKD in the US.…
January 15, 2024

Read more

VIEWPOINTS_Sergey Yurasov_2023
VIEWPOINTS

Sergey Yurasov Shares Insights on Initial Dose Escalation Data of BDTX-1535 for the Treatment of Non-Small Cell Lung Cancer Patients

Shots:   During the initial part of conversation, Sergey discussed details about the BDTX-1535 and the trial design of the P-I study where 1535 is being investigated in NSCLC and GBM patients   He then discussed the insights drawn from the first 51 patients recruited in the dose escalation part of the P-I study  In the final…
October 3, 2023

Read more